Speakers

Val Adams, Lowell Anthony, Tom Badgett, Elizabeth Beckman, Christine Brainson, Renier Brentjens, Michael Brooks, Holly Chitwood, Don Cohen, Virgilius Cornea, Jessica Croley, Tianyan Gao, Zhonglin Hao, Gerhard Hildebrandt, Jill Kolesar, Sameera Kumar, Aleksander Lenert, Adam Lye, Aju Mathew, Rachel Miller, Gregory Monohan, Rachael Morgan, Edward Romond, Jeffrey Sosman, William St Clair, Ravneet Thind, John Villano

Val Adams, PharmD, BCOP, FCCP

Associate Professor of Pharmacy
Program Director, PGY2 Specialty Residency Hematology/Oncology
College of Pharmacy
University of Kentucky

Val Adams obtained his BS Pharmacy, University of Utah, 1991; PharmD, University of Texas at Austin jointly with the University of Texas Health Science Center at San Antonio, 1993. He did his training in Specialty Residency in Hematology/Oncology, Audie L. Murphy VA Hospital, San Antonio, Texas, 1994; Fellowship in Immunology and Transplantation, University of Florida, 1996. Val specializes in Hematology/Oncology, Bone Marrow Transplantation. His research interests include Chemotherapy-induced hematopoietic toxicity, hematopoietic-stimulating cytokines, pain control, nutritional effects on chemotherapy.

Back to top

Lowell Anthony, MD, FACP

Professor, Medicine
University of Kentucky College of Medicine
Chief, Medical Oncology
UK HealthCare
Lexington, Kentucky

Dr. Anthony earned his undergraduate degree from King College in Bristol, Tennessee, and his MD and postgraduate training in medical oncology and clinical pharmacology at Vanderbilt University Medical Center in Nashville, Tennessee.

Dr. Anthony is board certified by the American Board of Internal Medicine and the American Board of Internal Medicine, Medical Oncology. He is a Fellow of the American College of Physicians.

Prior to joining the University of Kentucky, he was a Professor of Medicine at LSUHSC in New Orleans.

Dr. Anthony is an active member of several professional organizations. He has served on committees with the American Society of Clinical Oncology and the American Society of Clinical Pharmacology and Therapeutics. He is a member of the American Association for Cancer Research, American Federation of Medical Research, Southern Society for Clinical Investigation, and a founding member and on the Board of Directors of the North American Neuroendocrine Tumor Society (NANETS) for five years.

Dr. Anthony also has been among the “Best Doctors” in the US for the past 7 years.

Dr. Anthony has served as Chairman of the Cancer Committee for the Medical Center of Louisiana Hospital Cancer Program and on the Advisory Board for the General Clinical Research Center. His work has appeared in the Journal of Clinical Oncology, the Italian Journal of Gastroenterology, Cancer Research, Clinical Pharmacology Therapeutics, the British Journal of Clinical Pharmacology, the American Journal of Surgery, the Journal of Nuclear Medicine and the Annals of Internal Medicine. He has written and co-authored many book chapters, abstracts, and audiovisual media. He is a reviewer for the Journal of Nuclear Medicine, the New England Journal of Medicine, Annals of Internal Medicine, and the Journal of Clinical Oncology and Cancer among other publications. He has been a guest lecturer at numerous national and international scientific forums.

Back to top

Tom Badgett, MD

Assistant Professor of Pediatric Hematology/Oncology
Kentucky Children's Hospital
University of Kentucky
Lexington, Kentucky

Tom C. Badgett earned his medical degree from the University of Louisville and his doctorate in molecular biology from the University of Kentucky. He completed an internship and residency in the Department of Pediatrics at University of Louisville and Kosair Children’s Hospital.

Dr. Badgett came to Kentucky Children’s Hospital from The Johns Hopkins University School of Medicine and the National Institutes of Health where he was a pediatric hematology/oncology fellow. His research at the National Cancer Institute focused on next-generation sequencing of pediatric solid tumor genomes.

He is a member of the American Society of Clinical Oncology, the American Society of Hematology and the American Society of Pediatric Hematology and Oncology. In 2010 he was awarded the Scholar in Training Award by the American Association of Cancer Research, the Fellows Award for Research Excellence by the National Institutes of Health and the Best Oral Presentation at the Advances in Neuroblastoma Research conference in Stockholm, Sweden.

Back to top

Elizabeth Beckman, PharmD, BCPS, BCPPS, BCCCP

Clinical Knowledge Management Analyst
Office of the Executive Vice President for Health Affairs, UK Healthcare
Lexington, Kentucky

Elizabeth Beckman is a pharmacist and Clinical Knowledge Management Analyst at UK HealthCare in Lexington, Kentucky. She is responsible for the provision, implementation, and curation of clinical practice guidelines for the University of Kentucky Enterprise. Dr. Beckman received her PharmD from Butler University in Indianapolis, completed a PGY1 and PGY2 Pediatrics pharmacy residency at Indiana University Health, and is board certified in pharmacotherapy, pediatrics, and critical care pharmacy.

Back to top

Christine Brainson, PhD

Assistant Professor
Toxicology and Cancer Biology
University of Kentucky College of Medicine
Lexington, Kentucky

In September 2016, I joined the University of Kentucky Department of Toxicology and Cancer Biology, where my laboratory integrates studies of epigenetic programs, stem cell biology, and precision cancer medicine. I trained at the Dana-Farber Cancer Institute with Dr. Charles Roberts studying cancer epigenetics, at Tufts University with Dr. Charlotte Kuperwasser studying cellular hierarchies within tumors, and at Boston Children’s Hospital and Harvard Genetics with Dr. Carla Kim studying lung cancer subtypes and epigenetic therapies. During my post-doctoral work, I found a mechanism of synergy between EZH2 inhibitors and the chemotherapy etoposide (Nature 2015) and characterized the tumor propagating cells in the Lkb1/Pten murine squamous lung cancer model (Cancer Cell 2014). Most recently, I demonstrated that EZH2 inhibition up-regulates a squamous transcriptional program (Nature Communications 2017), and that distinct lung stem cells can be transformed and take on squamous characteristics. These findings inspired the current funded studies in my laboratory, which include testing inhibitors of epigenetic readers and writers in subtype specific lung cancers, understanding the epigenetic states that are most permissive for lung cancer transformation, and combining immunotherapies and epigenetic therapies for the treatment of lung cancer

Back to top

Renier Brentjens, MD, PhD

Director, Cellular Therapeutics
Memorial Sloan Kettering Cancer Center
New York, New York

Renier Brentjens, MD, PhD, obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service. As a medical oncology fellow during his training at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells” currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens expressed on other tumors including targeting the MUC-16 antigen expressed on ovarian carcinomas as well as the more ubiquitous WT-1 tumor associated antigen. These latter projects are similarly in the process of translation to the clinical setting.

Back to top

Michael Brooks, MD

Associate Professor, Radiology and Internal Medicine
University of Kentucky College of Medicine
Chief, Cardiovascular and Thoracic Radiology
Vice Chair, Radiology
UK HealthCare
Lexington, Kentucky

Dr. Brooks earned an MD from the University of Florida College of Medicine in Gainesville, Florida. He completed residency and a fellowship in Cardiothoracic Imaging at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina. He is certified by the American Board of Radiology, Diagnostic Radiology, and is a NIOSH B Reader.

Research interests include evaluating low dose computed tomography and serum biomarkers for lung cancer screening. Dr. Brooks serves as investigator and co-investigator on numerous research grants funded by the National Cancer Institute, Department of Defense, and the Kentucky Lung Cancer Research Program. Dr. Brooks served as co-investigator and Radiology Chair on the Marty Driesler Lung Cancer Screening Research Project, an investigator-initiated trial of the Markey Cancer Center conducted in Kentucky’s 5th district. He is also interested in the development and delivery of several continuing medical education series for radiologists, primary care, and other healthcare practitioners on lung cancer.

Clinical interests include Cardiovascular MRI and CT, High Resolution Computed Tomography (CT) of Lung, Lung Cancer, and Occupational Lung Diseases.

Back to top

Holly Chitwood, MSN, DNPc, APRN, FNP-B

Clinical Instructor of Pediatrics
University of Kentucky College of Medicine
Lexington, Kentucky

Holly Chitwood is an advanced nurse practitioner at the Medical Oncology Program of Markey Cancer Center. She began her career as a staff nurse in the field of Pediatric Hematology/Oncology with Kentucky Children's Hospital in 2006. She earned a bachelor's of science in social work from the University of the Cumberlands in 2001. She completed an associate degree in nursing at Eastern Kentucky University in 2006 and a bachelor's degree in nursing from Eastern Kentucky University in 2014. She completed a master's degree in nursing in 2015 at Lincoln Memorial University. Chitwood is a board certified family nurse practitioner and has completed the post masters Acute Care ( ACNP) program at university and is enrolled in DNP and then as Post–Masters Degree Acute Care Nurse Practitioner UK CON and DNP.

Back to top

Don Cohen, PhD

Director, Flow Cytometry and Cell Sorting Shared Resource Facility
University of Kentucky College of Medicine
Lexington, Kentucky

Don Cohen, PhD is a professor of immunology in the Department of Microbiology, Immunology, and Molecular Genetics at the University of Kentucky. He has over 35 years of research experience in cellular immunology with an emphasis on innate immune responses. He has published over 100 scientific articles in the area of cellular immunology. Over the last 25 years, he has been the director of the Flow Cytometry & Cell Sorting core facility at UK, which provides flow cytometry and immune monitoring services to researchers at UK.

Back to top

Virgilius Cornea, MD

Assistant Professor
Pathology and Laboratory Medicine
University of Kentucky College of Medicine
Lexington, Kentucky

My name is Virgilius Cornea; I received my medical degree from Timisoara University of Medicine and Pharmacy, Timisoara, Romania. I then completed a fellowship in Kidney and Transplant Pathology at the University of Pittsburgh Medical Center, in Surgical Pathology at Mt. Sinai School of Medicine, New York and in Anatomical Pathology at SUNY Downstate Medical Center, Brooklyn, N.Y.

I am board certified by the American Board of Pathology in Anatomic and Clinical Pathology.

Back to top

Jessica Croley, MD

Medical Oncologist
KentuckyOne Health Cancer Care
Saint Joseph East
Lexington, Kentucky

I am a practicing medical oncologist at KentuckyOne Health Cancer Care, Saint Joseph East in Lexington. My clinical practice does have a focus in treatment of breast cancer, but I treat all hematologic and solid organ malignancy. I trained at UK for undergrad (dual degrees in Chemistry and Biotechnology). I graduated from Medical School at UK in 2007 and then completed residency in Internal Medicine (2010) as well as fellowship in Hematology and Medical Oncology (2013) at UK. I have a strong interest in Precision Medicine, participate in Markey Molecular Tumor Board. I am part of the Catholic Health Institute for Research and Innovation (CIRI), which is a NCI designated community oncology research program (NCORP). We have 60 clinical trials open currently, many evaluating immune and targeted therapies.

Back to top

Tianyan Gao, PhD

Professor, Molecular & Cellular Biochemistry
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Dr. Tianyan Gao is a Professor of Cellular and Molecular Biochemistry and an investigator of the Markey Cancer Center at the UK College of Medicine. She received her PhD degree in Pharmacology from Northwestern University, and she subsequently received her postdoctoral training at the University of California San Diego. Her lab’s research focuses on the function and regulation of signal transduction pathways in colorectal cancer. Dr. Gao’s research program has been continuously funded by NIH and other private foundations for over 10 years. She has also mentored a number of students, postdoctoral followers and medical residents.

Back to top

Zhonglin Hao, MD

Associate Professor
Thoracic Oncology Program
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Dr.Hao graduated from Inner Mongolia Medical College in Northern China. He subsequently pursued his passion in research and earned a PhD in molecular biology and biochemistry in the University of Tokyo. Following a productive postdoctoral period in the University of Virginia, he got back to medicine. He trained in internal medicine in Mercer University School of Medicine and in Hematology and Oncology in Emory’s Winship Cancer Institute. Joined the Medical College of Georgia as a faculty in 2010, he is board certified in both hematology and medical oncology. Joined the Markey Cancer Center as associate professor of Medicine in Dec 2017, he specializes in aerodigestive cancers with research interests in immunotherapeutics and molecular diagnostics. He coauthored more than 40 scientific papers. He is PI of multiple Investigator Initiated Trials.

Back to top

Gerhard Hildebrandt, MD

Professor, Medicine
University of Kentucky College of Medicine
Division Chief, Hematology and Blood & Marrow Transplantation
UK HealthCare
Lexington, Kentucky

Dr. Hildebrandt earned a medical degree from the Johannes Gutenberg University of Mainz Medical School, Germany. Upon completing his doctoral research thesis, he was awarded the "doctor medicinae" with magna cum laude. He completed a residency in Internal Medicine and a Hematology and Oncology fellowship at the University of Regensburg, Germany, and became Bone Marrow Transplant and Hematologic Malignancies Attending at the University of Regensburg. In 2009, he was awarded the "Habilitation", the highest academic qualification a scholar can achieve by own pursuit in Germany.

After moving to the United States, he was a faculty member at the Louisiana State University in Shreveport and at the University of Utah. He was the director of the bone marrow transplant program at LSUHSC Shreveport and director of the Utah Blood and Marrow Transplant program at the Huntsman Cancer Institute/University of Utah before moving to Kentucky.

He is a member of ASH, ASCO, ASBMT, AACR, the author of more than forty articles, books, and book chapters and is strongly involved in clinical trials.

Dr. Hildebrandt focuses on patients with cancers of the blood and lymph system, patients before and after blood or marrow stem cell transplantation, and on patients suffering from acute and chronic graft versus host disease.

Back to top

Jill Kolesar, PharmD, MS, FCCP, BCPS

Co-Director, Molecular Tumor Board
University of Kentucky College of Pharmacy
Lexington, Kentucky

Dr. Jill Kolesar is Professor of Pharmacy at the University of Kentucky and holds administrative positions at the Markey Cancer Center as the Director of the Early Phase Clinical Trials Center, Co-Chair of the Molecular Tumor Board, and the Co-Leader of the Developmental Therapeutics Program. Jill received her BS in pharmacy at the University of Wisconsin and her Doctor of Pharmacy degree at the University of Texas Health Science Center in San Antonio, where she also completed a specialty practice residency in oncology/hematology and a fellowship in molecular oncology pharmacotherapy. She received an MS in Epidemiology with an emphasis in Genetic Epidemiology from the University of Wisconsin in 2016. After 15 years as a clinical pharmacist in the hematology clinic at Madison’s VA hospital, Dr. Kolesar transitioned her clinical practice to the UW Comprehensive Cancer Center where she co-chaired the Molecular Tumor Board, a multi-disciplinary group that reviews somatic mutations and recommends therapy targeted to those mutations for patients with cancer. Her research focuses on the drug development of anticancer agents with an emphasis on targeted therapies and biomarkers. She has authored more than 200 abstracts, research articles, and book chapters, and as a principal investigator she has received more than $1.5 million in research funding from the NCI, American Cancer Society and other sources. Jill has received teaching and research awards from local, national and international organizations including the Innovations in Teaching Award from the American Association of Colleges of Pharmacy.

Back to top

Sameera Kumar, MD

Chief Resident
Radiation Oncology
University of Kentucky College of Medicine
Lexington, Kentucky

Dr. Kumar is the chief resident at the University of Kentucky Department of Radiation Oncology. Next year she will join the Radiation Oncology faculty at Fox Chase. She has an interest in lung cancer and the immunostimulatory effects of radiation in lung cancer.

Back to top

Aleksander Lenert, MD, FRCPC

Assistant Professor, Medicine
University of Kentucky College of Medicine
Lexington, Kentucky

Dr. Lenert earned a medical degree from the University of Ottawa Faculty of Medicine in Ontario, Canada. He completed residency training in Internal Medicine and fellowship training in Rheumatology at the Cleveland Clinic. Dr. Lenert is dual board-certified by the American Board of Internal Medicine (ABIM) in Internal Medicine and Rheumatology and by the Royal College of Physicians and Surgeons of Canada in Internal Medicine and Rheumatology.

Clinical interests include Adult Onset Still’s Disease, Dermatomyositis and Polymyositis, Lupus, Macrophage Activation Syndrome, Osteoporosis, Psoriatic Arthritis, Rheumatoid Arthritis, and Vasculitis.

Back to top

Adam Lye, MD

Medical Director
Hardin Memorial Hospital
Cancer Care Center
Elizabethtown, Kentucky

Originally from Taylor Mill, KY (Northern Kentucky). Attended undergraduate, medical school, residency, and fellowship at the University of Kentucky. Full time medical oncologist and medical director for the Cancer Care Center at Hardin Memorial Hospital in Elizabethtown, KY which services over 400,000 patients

Back to top

Aju Mathew, MD, MPhil

Assistant Professor of Medicine
Medical Oncology
University of Kentucky
College of Medicine
Lexington, Kentucky

Aju Mathew, MD, MPhil, completed graduate school at the University of Cambridge in the United Kingdom and received his medical degree at the University of Kerala in Thiruvananthapuram, Kerala, India. He then completed a residency and a fellowship in Hematology and Oncology at the University of Pittsburgh Medical Center.

Mathew is board certified by the American Board of Internal Medicine.

Back to top

Rachel Miller, MD

Associate Professor
Obstetrics and Gynecology
University of Kentucky College of Medicine
Lexington, Kentucky

My name is Rachel Ware Miller; I received my medical degree from the University of Kentucky, College of Medicine. I then completed a fellowship at the University of Kentucky.

I am board certified by the American Board of Obstetrics and Gynecology in Obstetrics and Gynecology and Gynecologic Oncology.

I'm a gynecological oncologist, which means that I did specialized training after an OB-GYN residency to focus on cancers of the female reproductive tract. These include uterine, cervical, vulvar, vaginal and ovarian cancers. I love being able to practice medicine in the state where I grew up. After returning from my residency at Dartmouth, I realized how well I relate to people here in Central Kentucky. I grew up around these people, they're who I know.

I place a lot of importance on making the patient and their family feel comfortable. I really enjoy hearing the variety of replies that I get from patients when I ask how they spend their day-to-day and just hearing about the unique aspects of their lives. I see patients here locally as well as from rural parts of the state, and I think that's one of the things that I enjoy most. I see patients of all ages who are from a variety of backgrounds, education levels and social circumstances, and I really enjoy that aspect.

Back to top

Gregory Monohan, MD

Associate Professor
Department of Hematology and Blood & Marrow Transplantation
Fellowship Director, Hematology/Medical Oncology
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Dr. Monohan received his MD from the University of Kentucky College of Medicine. He served his residency with the Indiana University School of Medicine and a fellowship with the University of Kentucky. Dr. Monohan's clinical interests include benign and malignant hematology, blood and marrow transplantation and multiple myeloma. He is certified with the American Board of Internal Medicine, Hematology and Medical Oncology.

Back to top

Rachael Morgan, PharmD BCOP

Hematology/Oncology Clinical Pharmacist
Markey Cancer Center
UK Healthcare
Lexington, Kentucky

Dr. Morgan received her Doctor of Pharmacy degree from the University of Kentucky. She then completed a PGY1 pharmacy practice residency at Indiana University Health in Indianapolis and a PGY2 specialty residency in hematology/oncology at the University of Kentucky Medical Center.

Dr. Morgan provides comprehensive pharmaceutical care to patients at UK’s Markey Cancer Center, primarily practicing in the Multidisciplinary Clinic and on the inpatient medicine service dedicated to the care of oncology patients. Teaching activities include precepting students and residents on ambulatory oncology rotations and the inpatient medical oncology service, and participating in the oncology therapeutics curriculum at the UK College of Pharmacy. Her research interests include brain tumors, immunotherapy, patient outcomes and opioid stewardship.

Back to top

Edward Romond, MD

Professor, Medicine
University of Kentucky College of Medicine
Lexington, Kentucky

Dr. Romond is a graduate of University of Kentucky College of Medicine and completed residency and fellowship at Michigan State University in East Lansing.

He is certified by the American Board of Internal Medicine, American Board of Internal Medicine, Hematology, and American Board of Internal Medicine, Medical Oncology. He received the Leonard Tow 2003 Humanism in Medicine Award.

Dr. Romond has been the principal investigator for the National Surgical Adjuvant Breast and Bowel Project (NSABP) adjubant studies at the University of Kentucky since 1985. He currently serves on the Board of Directors of the NSABP Foundation and is the Chair of the NSABP Membership Committee. He is the protocol chair for NSABP B-31, one of the landmark studies that demonstrated the efficacy of trastuzumab in the adjuvant treatment of HER2-positive breast cancer. He also serves as the Medical Director for the Markey Cancer Center Genetics Counseling Program.

Clinical interests include Adult Hemophilia, Breast Cancer, and Medical Oncology.

Back to top

Jeffrey Sosman, MD

Professor
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

I have been an active clinical investigator vested in the immune-based therapy of melanoma. This has led to my role in the clinical development of initially Interleukin-2 and more recently anti-CTLA-4 and anti-PD1/PDL-1. While checkpoint therapy has been a great breakthrough in cancer treatment, additional immune-based strategies are still critically needed. Efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance are one of my major interest. In addition I have ongoing efforts in the personalized therapy of melanoma with well-defined targets (BRAF v600, NRAS mutations, CKIT mutations). I co-lead the Northwestern Cancer Center Translational Research in Solid Tumors (TRIST) program which is critical to the success of the Cancer Center. In this role, I am working to bring translational studies including immunotherapy based trials to all solid tumors. The development of translational studies that will provide a better understanding to sensitivity and resistance to both immune checkpoint therapy and targeted therapy is my highest priority. As Co-Leader of TRIST program, I am determined to bring creative immune based trials to cancers .

Back to top

William St Clair, MD, PhD

Professor Department of Radiation Medicine
Co-Director, Gamma Knife Radiosurgery Center
University of Kentucky College of Medicine
Lexington Kentucky

My name is William St. Clair; I received my medical degree from the University of Kentucky, College of Medicine, Lexington. I then completed a fellowship at Harvard University Medical Center, Boston. I am board certified by the American Board of Radiology in Radiation Oncology.

Back to top

Ravneet Thind, MD

Assistant Professor
Internal Medicine
University of Kentucky College of Medicine
Lexington, Kentucky

My name is Ravneet Thind I received my medical degree from Kasturba Medical College Karnataka India I then completed fellowships in NeuroOncology and Hematology/Oncology at Henry Ford Hospital Detroit I am board certified by the American Board of Internal Medicine

Back to top

John Villano, MD, PhD

Director of Clinical Neuro-Oncology
Professor, Depts. of Medicine, Neurosurgery, and Neurology
University of Kentucky
Lexington, Kentucky

Dr. John Villano specializes in the treatment of brain cancers. He will advance UK's Clinical Neuro-Oncology Research Program, serving as its director. Dr. Villano served as the director of medical Neuro-Oncology at the University of Illinois Medical Center. He earned an MD and PhD at the University of Texas Southwestern Medical School at Dallas and trained in neurology at the University of Michigan. He also completed a fellowship in hematology/oncology at the University of Chicago. Dr. Villano is a former American Society of Clinical Oncology track leader for CNS tumors. Currently, he is on the board of the Central Brain Tumor Registry US. He is also a member of the Neuro-Oncology Committee in the cooperative group ALLIANCE and a Society of Neuro-Oncology committee member.

Back to top